Generative AI has taken the world by storm ever since the launch of ChatGPT in 2022. This has ushered in a new urgency to find applications of Generative AI in medicine. However, past revolutions in AI that have changed entire industries often struggled to translate these transformative impacts to medicine. One hurdle for AI in medicine is the lack of large-scale datasets. In this webinar, we will talk to visionaries who have spent years curating clinical trial datasets to celebrate their data’s story and hear their thoughts on how this data can be used by AI to transform medicine.
Dr. Greenberg is a board-certified rheumatologist with multiple leadership positions at CorEvitas, part of Thermo Fisher Scientific. He led the development and launch of multiple CorEvitas registries across medical specialties, including rheumatology, dermatology, gastroenterology, and neurology, working with investigators in Europe, Latin America, and Japan. These registries have supported client post-authorization safety studies as part of post-marketing requirements for both FDA and EMA. Prior to CorEvitas, Dr. Greenberg spent over ten years in academic medicine in the Division of Rheumatology at the NYU Langone School of Medicine, leading and collaborating on multiple NIH and AHRQ grants. Dr. Greenberg has authored or co-authored over 100 manuscripts, with expertise in comparative effectiveness and comparative drug safety studies. He continues to see rheumatology patients at Overlook Medical Center in Summit, NJ.
Dr. Klaus Romero is a prominent clinician-scientist and scholar who serves as Chief Science Officer at Critical Path Institute. As a recognized thought leader, Dr. Romero established C-Path’s Quantitative Medicine Program and has been an instrumental leader in the growth of the organization’s portfolio of transformative consortia and public-private partnerships across more than 16 medical product development areas. As a scientist and an executive, Dr. Romero led the generation of actionable drug development tools for Alzheimer’s disease, which introduced a transformation in the drug development process for this indication. In tuberculosis, Romero’s leadership was instrumental in generating a drug development infrastructure that allowed the approval of the first individual drug and the first new regimen for this disease in more than 50 years. Dr. Romero’s leadership has also resulted in the transformation of medical product development paradigms for many other diverse areas, like polycystic kidney, Parkinson’s, and Huntington’s diseases, as well as type 1 diabetes prevention, kidney transplantation, Duchenne muscular dystrophy, and several other rare and orphan indications. As a trained clinical pharmacologist and epidemiologist, Dr. Romero is a fellow of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, as well as a member of the American Society for Clinical Pharmacology and Therapeutics, and the International Society of Pharmacoepidemiology. He is also an Associate Research Professor at the University of Arizona and an Adjunct Professor at the University of Southern California and Arizona State University.
Alex is a physicist who loves tackling tough technological challenges involving machine learning. For the past five years, Alex has been working on autonomous vehicles at Motional (previously called nuTonomy) and Cruise. He initially developed novel lidar detection algorithms before becoming a leader in managing teams tackling perception and prediction problems in self-driving. Previously, he was a postdoctoral fellow at the Salk Institute. Alex received his Ph.D. in physics from Boston University and a B.S. in Physics and Mathematics from the University of Wisconsin.